Low Molecular Weight Alginate Oligosaccharides as Alternatives to PEG for Enhancement of the Diffusion of Cationic Nanoparticles Through Cystic Fibrosis Mucus
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202400510 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Ruhina Maeshima und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, WC1N 1EH, UK. Hauptthemen laut MEDLINE: Cystic Fibrosis, Alginates, Polyethylene Glycols, Nanoparticles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research Biomedical Research Centre, Norges Forskningsråd, NIHR Great Ormond Street Hospital Biomedical Research Centre.
Abstract (Originalsprache)
Airway mucus is a major barrier to the delivery of lipid‐based nanoparticles in chronic airway diseases such as cystic fibrosis (CF). Receptor‐Targeted Nanocomplexes (RTN), comprise mixtures of cationic lipids and bifunctional peptides with receptor‐targeting and nucleic acid packaging properties. The aim of this study is to improve the mucus‐penetrating properties of cationic siRNA and mRNA RTNs by combining them with low molecular weight alginate oligosaccharides, OligoG and OligoM. Cationic RTNs formulated with either alginate become strongly anionic, while PEGylated messenger RNA (mRNA) and short interfering RNA (siRNA) RTNs remain cationic. Both alginates enhance mucus diffusion rates of cationic siRNA and mRNA RTNs in a static mucus barrier diffusion model, with OligoG particularly effective. PEGylation also enhance mucus diffusion rates of siRNA RTNs but not mRNA RTNs. Electron microscopy shows that RTNs remained intact after mucosal transit. The transfection efficiency of OligoM‐coated mRNA RTNs is better than those coated with OligoG or PEG, and similar to cationic RTNs. In siRNA RTN transfections, OligoM is better than OligoG although 1% PEG is slightly better than both. The combination of cationic RTNs and alginate oligosaccharides represents a promising alternative to PEGylation for epithelial delivery of genetic therapies across the mucus barrier while retaining transfection efficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, WC1N 1EH, UK.
- Institute of Pharmaceutical Science, Faculty of Life Science and Medicine, King's College London, 15- Stamford Street, London, SE1 9NH, UK.
- AlgiPharma AS, Industriveien 33, Sandvika, Akershus, 1337, Norway.
- Department of Biotechnology and Nanomedicine, SINTEF Industry, Strindvegen 4, Trondheim, 7034, Norway.
ORCID-Profile: Ruhina Maeshima, Stephen L Hart
Förderung
- National Institute for Health Research Biomedical Research Centre
- Norges Forskningsråd
- NIHR Great Ormond Street Hospital Biomedical Research Centre
Zitieren
APA
Maeshima, R., Tagalakis, A. D., Gyftaki-Venieri, D., Jones, S. A., Rye, P. D., Tøndervik, A., Åstrand, O. A. H., & Hart, S. L. (2025). Low Molecular Weight Alginate Oligosaccharides as Alternatives to PEG for Enhancement of the Diffusion of Cationic Nanoparticles Through Cystic Fibrosis Mucus. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202400510
Vancouver
Maeshima R, Tagalakis AD, Gyftaki-Venieri D, Jones SA, Rye PD, Tøndervik A, et al. Low Molecular Weight Alginate Oligosaccharides as Alternatives to PEG for Enhancement of the Diffusion of Cationic Nanoparticles Through Cystic Fibrosis Mucus. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202400510
BibTeX
@article{Maeshima2025,
author = {Maeshima, Ruhina and Tagalakis, Aristides D and Gyftaki-Venieri, Dafni and Jones, Stuart A and Rye, Philip D and Tøndervik, Anne and Åstrand, O Alexander H and Hart, Stephen L},
title = {Low Molecular Weight Alginate Oligosaccharides as Alternatives to PEG for Enhancement of the Diffusion of Cationic Nanoparticles Through Cystic Fibrosis Mucus},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202400510}
}
EUVIMED